CN104095857A - 闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 - Google Patents
闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 Download PDFInfo
- Publication number
- CN104095857A CN104095857A CN201410304395.4A CN201410304395A CN104095857A CN 104095857 A CN104095857 A CN 104095857A CN 201410304395 A CN201410304395 A CN 201410304395A CN 104095857 A CN104095857 A CN 104095857A
- Authority
- CN
- China
- Prior art keywords
- hepatic fibrosis
- muell
- miq
- arg
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 title 1
- GEIFQLXIDUDMNZ-PCJVTFPHSA-N (4aR,4bR,6aR,8S,10aR,10bR,12R,12aR)-12-hydroxy-1,1,1',1',4a,10a,10b-heptamethyl-3'-methylidenespiro[3,4,4b,5,6,6a,7,9,10,11,12,12a-dodecahydrochrysene-8,2'-cyclopentane]-2-one Chemical compound CC1(C)CCC(=C)[C@@]11C[C@@H](CC[C@H]2[C@]3(C[C@@H](O)[C@H]4C(C)(C)C(=O)CC[C@@]42C)C)[C@@]3(C)CC1 GEIFQLXIDUDMNZ-PCJVTFPHSA-N 0.000 claims description 27
- XURLTFUKDPZAPN-QFIPXVFZSA-N Cleistanone Natural products O(C)[C@H]1OC(=O)c2c(-c3cc4OCOc4cc3)c3c(c(O)c12)cc(OC)c(OC)c3 XURLTFUKDPZAPN-QFIPXVFZSA-N 0.000 claims description 27
- 241000785597 Cleistanthus Species 0.000 claims description 27
- 150000002576 ketones Chemical class 0.000 claims description 25
- 239000002023 wood Substances 0.000 claims description 25
- 241001597008 Nomeidae Species 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 14
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 7
- 102000013275 Somatomedins Human genes 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 230000003328 fibroblastic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000012190 activator Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OBDKRSAWIALNLH-UHFFFAOYSA-N CCCCC(C)C(CC)(CC1)CC(CC2)C1(C)C(C)(CC1/[O]=C/CBr)C2C(C)(CC2)C1C(C)(C)C2O Chemical compound CCCCC(C)C(CC)(CC1)CC(CC2)C1(C)C(C)(CC1/[O]=C/CBr)C2C(C)(CC2)C1C(C)(C)C2O OBDKRSAWIALNLH-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410304395.4A CN104095857B (zh) | 2014-06-27 | 2014-06-27 | 闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410304395.4A CN104095857B (zh) | 2014-06-27 | 2014-06-27 | 闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104095857A true CN104095857A (zh) | 2014-10-15 |
CN104095857B CN104095857B (zh) | 2016-07-13 |
Family
ID=51664652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410304395.4A Active CN104095857B (zh) | 2014-06-27 | 2014-06-27 | 闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104095857B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104672295A (zh) * | 2015-03-10 | 2015-06-03 | 南京大学 | 闭花木酮的o-(三唑基)乙基衍生物及其制备方法和应用 |
CN104840471A (zh) * | 2015-04-15 | 2015-08-19 | 南京广康协生物医药技术有限公司 | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备抗肝纤维化药物中的应用 |
CN104906089A (zh) * | 2015-05-27 | 2015-09-16 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗缺氧药物中的应用 |
CN104922120A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗肝纤维化药物中的应用 |
CN104922122A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
CN104922121A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备升高白细胞的药物中的应用 |
WO2020119424A1 (zh) | 2018-12-14 | 2020-06-18 | 中国药科大学 | 一种含有sumo抑制剂的组合物及应用 |
-
2014
- 2014-06-27 CN CN201410304395.4A patent/CN104095857B/zh active Active
Non-Patent Citations (2)
Title |
---|
VAN TRINH THI THANH, ET AL.: "Cleistanone: A Triterpenoid from Cleistanthus indochinensis with a New Carbon Skeleton", 《EUR. J. ORG. CHEM.》, 7 June 2011 (2011-06-07), pages 4108 - 4111 * |
罗奕 等: "齐墩果酸对四氯化碳所致大鼠肝纤维损伤的保护作用", 《中国药师》, vol. 17, no. 3, 5 March 2014 (2014-03-05), pages 378 - 381 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104672295A (zh) * | 2015-03-10 | 2015-06-03 | 南京大学 | 闭花木酮的o-(三唑基)乙基衍生物及其制备方法和应用 |
CN104840471A (zh) * | 2015-04-15 | 2015-08-19 | 南京广康协生物医药技术有限公司 | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备抗肝纤维化药物中的应用 |
CN104906089A (zh) * | 2015-05-27 | 2015-09-16 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗缺氧药物中的应用 |
CN104922120A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗肝纤维化药物中的应用 |
CN104922122A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
CN104922121A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备升高白细胞的药物中的应用 |
WO2020119424A1 (zh) | 2018-12-14 | 2020-06-18 | 中国药科大学 | 一种含有sumo抑制剂的组合物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104095857B (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104095859B (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗肝纤维化药物中的应用 | |
CN104095857A (zh) | 闭花木酮Cleistanone的二乙胺衍生物在制备抗肝纤维化药物中的应用 | |
CN105693815B (zh) | 一种哌嗪修饰的乌索酸衍生物及其制备方法和应用 | |
CN104434928B (zh) | 闭花木酮的o-(哌嗪基)乙基衍生物在制备抗肝纤维化药物中的应用 | |
CN104086617A (zh) | 闭花木酮Cleistanone的二甲胺衍生物、制备方法及其用途 | |
CN104188980B (zh) | 闭花木酮Cleistanone的O-(吗啉基)乙基衍生物、制备方法及其用途 | |
CN104840471A (zh) | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备抗肝纤维化药物中的应用 | |
CN105497037A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN104672295A (zh) | 闭花木酮的o-(三唑基)乙基衍生物及其制备方法和应用 | |
CN106038527A (zh) | Artalbic acid的衍生物的组合物用于制备抗肝纤维化药物 | |
CN104922120A (zh) | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备抗肝纤维化药物中的应用 | |
CN104825448A (zh) | Daphmalenine A衍生物在制备抗肝纤维化药物中的应用 | |
CN106727571A (zh) | Psiguadial A的哌嗪基和1H‑四氮唑基衍生物组合物用于抗肝纤维化 | |
CN105193792A (zh) | 组合物及其在抗肝纤维化药物中的应用 | |
CN105267196A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN105078988A (zh) | 组合物67083001030512及其在抗肝纤维化药物中的应用 | |
CN105287566A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN105250301A (zh) | 组合物77092202050623及其在抗肝纤维化药物中的应用 | |
CN105497031A (zh) | 组合物及其在抗肝纤维化药物中的应用 | |
CN106727531A (zh) | Psiguadial A的苯并咪唑基和二氯乙胺基衍生物组合物用于抗肝纤维化 | |
CN105250291A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN105287588A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN105287466A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN105287597A (zh) | 一种组合物及其在抗肝纤维化药物中的应用 | |
CN105125555A (zh) | 组合物及其在抗肝纤维化药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Fei Ziwei Inventor after: Jiang Chunping Inventor after: Qiang Guanghui Inventor after: Ji Anlai Inventor after: Wu Junhua Inventor after: Lu Xian Inventor after: Gao Lin Inventor after: Wu Junyi Inventor after: Huang Rong Inventor before: Gao Lin Inventor before: Huang Rong Inventor before: Wu Junyi Inventor before: Wu Junhua |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |